Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.51 USD
-0.17 (-1.34%)
Updated May 3, 2024 04:00 PM ET
After-Market: $12.74 +0.23 (1.84%) 4:44 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cidara Therapeutics (CDTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.50 | $40.00 | $25.00 | 156.31% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Cidara Therapeutics comes to $32.50. The forecasts range from a low of $25.00 to a high of $40.00. The average price target represents an increase of 156.31% from the last closing price of $12.68.
Analyst Price Targets (2 )
Broker Rating
Cidara Therapeutics currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 1 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.50 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/25/2024 | WBB Securities | Stephen G Brozak | Not Available | Strong Buy |
4/23/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
2/1/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 3 |
Average Target Price | $32.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -1.50 |